MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD 

• CHRONOS is one of the largest real-world studies including refractory GI-aGvHD patients (n=59) treated with third-line best available treatments other than microbiome-based therapy

• Results from CHRONOS have been presented at the upcoming EBMT 2026 Annual Congress and included 29% 12-month overall survival (OS) and 37% Day28 GI-overall response rate ( GI-ORR), supporting the urgent need for new therapeutic options

• CHRONOS results have been included in the MaaT013 (Xervyteg ®) Marketing Authorizat ion Application filed with the European Medicines Agency (EMA) to contextualize the third-line setting for patients suffering from GI-aGvHD and being resistant to prior lines of treatment

• MaaT013 (Xervyteg ®) Marketing Authorization application is currently under regulatory review by the EMA, with feedback anticipated mid-2026, based on EMA’s standard timelines

Lyon, France, April 1st, 2026 – 7.30 a.m. CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced the publication of CHRONOS, a large multicenter retrospective cohort study evaluating real-world- outcomes of third-line systemic therapies (excluding microbiotherapy) in 59 patients with steroid- and ruxolitinibrefractory aGvHD with gastrointestinal involvement in the peer‑reviewed journal Bone Marrow Transplantation, the official journal of the European Society for Blood and Marrow Transplantation (EBMT). The article is available here: Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure . The CHRONOS Press release 2/4 data have also been presented during a poster session by Johannes Clausen, MD, hematologist at Ordensklinikum Linz Elisabethinen, Hematology Department, Linz, Austria and primary author of the publication at the 2026 EBMT Annual Congress .

Read the press release